PHILADELPHIA The American Association for Cancer Research extends its sincere congratulations to Margaret Hamburg, M.D., on her nomination to lead the Food and Drug Administration (FDA).
As FDA commissioner, Hamburg will oversee the advancement of cutting-edge products and therapies that are central to the treatment and prevention of cancer. Her leadership will bring new perspectives to important FDA initiatives, such as devising regulatory pathways for biomarker approval and the development of therapies and tests, as well as efforts to develop the next generation of clinical trials.
The AACR is confident that she will provide the expertise, integrity and leadership needed to revitalize the agency's scientific foundation for the benefit of millions of cancer patients who depend on the agency to ensure the safety and efficacy of new therapies and products.
Hamburg's distinguished career as a physician-scientist and experience in state and federal government as assistant secretary for planning and evaluation at the U.S. Department of Health and Human Services, as New York City health commissioner, and her current position as senior scientist for the Global Health and Security Initiative, make her an ideal candidate to provide the FDA with a fresh vision for the future.
As the authoritative source of information about advances in the causes, diagnosis, treatment and prevention of cancer, the AACR looks forward to working with Hamburg as a resource to ensure the FDA maintains its prominence at the forefront of innovation and cutting-edge regulatory science.
|Contact: Jeremy Moore|
American Association for Cancer Research